ABOS
Acumen Pharmaceuticals Inc

1,259
Mkt Cap
$164.76M
Volume
2.22M
52W High
$3.05
52W Low
$0.8551
PE Ratio
-1.27
ABOS Fundamentals
Price
$2.81
Prev Close
$2.72
Open
$2.96
50D MA
$1.95
Beta
1.54
Avg. Volume
164,093.95
EPS (Annual)
-$1.71
P/B
1.83
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research
BTIG Research boosted their price objective on shares of Acumen Pharmaceuticals from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells $12,536.16 in Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of...
MarketBeat·16d ago
News Placeholder
Insider Selling: Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells 6,888 Shares of Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction dated Thursday, January 8th. The shares were sold at an...
MarketBeat·16d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Sells $14,820.26 in Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average...
MarketBeat·16d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,941 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941 shares of the business's stock in a transaction that occurred on Friday, January 9th. The stock was...
MarketBeat·16d ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company...
MarketBeat·18d ago
News Placeholder
James Doherty Sells 6,467 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider James Doherty sold 6,467 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average...
MarketBeat·19d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Matt Zuga Sells 5,100 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 5,100 shares of the business's stock in a transaction dated Tuesday, January 6th. The stock was sold at an average...
MarketBeat·21d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen
Wall Street Zen upgraded Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·1mo ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...
MarketBeat·1mo ago
<
1
2
...
>

Latest ABOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.